Baker IDI Heart & Diabetes Institute Holdings Ltd.
|Baker IDI Heart & Diabetes Institute Holdings Ltd. Patent applications|
|Patent application number||Title||Published|
|20140147445||Selective Targeting of the CD40L/Mac-1 Interaction by Small Peptide Inhibitors and its Use for the Treatment of Inflammation and Atherogenesis - The CD40L/Mac-1 interaction is selectively targeted by small peptide inhibitors and/or antibodies and such peptides are used for the specific treatment of inflammation and atherogenesis. In particular, pharmaceutical compositions comprising a polypeptide having the amino acid sequence EQLKKSKTL and antibodies specifically binding to an epitope are disclosed.||05-29-2014|
|20130034552||TEMPERATURE SENSITIVE CONJUGATE COMPOSITIONS, AND USES RELATED THERETO - This disclosure relates to temperature sensitive conjugates, compositions, and uses related thereto. In certain embodiments, the disclosure relates to conjugate polymers comprising a) a temperature sensitive polymer and b) an antibody. Typically the antibody has an epitope to a platelet receptor. The antibody may be a single-chain antibody wherein the platelet receptor is GPIIb/IIIa, such as an anti-GPIIb/IIIa antibody. In certain embodiments, the antibody binds specifically to the activated conformation of GPIIb/IIIa, i.e., an activation-specific GPIIb/IIIa antibody.||02-07-2013|